Biocompatibles is committed to delivering shareholder value by:
- developing and commercialising a range of products to treat various cancer indications so as to improve the survival chances and quality of life of cancer patients
- developing products for growing markets and adhering to aggressive timelines
- responsibly managing the Company's financial resources
Following the sales of the contact lens and cardiovascular stent businesses in 2002, Biocompatibles has returned £123m of capital to shareholders.
Presentations